Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Orphazyme analyse fra Red Eye

Planlagt Fastgjort Låst Flyttet Debatforum
9 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • A Offline
    A Offline
    Aps_invest
    wrote on sidst redigeret af
    #1

    https://www.redeye.se/research/794077/orphazyme-our-view-on-the-latest-news?utm_source=MB&utm_medium=email

    1 Reply Last reply
    1
    • A Offline
      A Offline
      Aps_invest
      wrote on sidst redigeret af
      #2

      Today, September 29, 2020 (CET), Orphazyme announces the pricing of the global offering at a price per new ordinary share of DKK 70.1844, corresponding to a price of USD 11.00 per ADS

      1 Reply Last reply
      1
      • U Offline
        U Offline
        uddi999
        wrote on sidst redigeret af
        #3

        Kan du give et resume af hvad der står i analysen. Er desværre låst.

        1 Reply Last reply
        0
        • T Offline
          T Offline
          Thorkild01
          wrote on sidst redigeret af
          #4

          Referat klippet fra Avanza forum:

          "We have been in contact with the Orphazyme team. We are reassured about the NDA process with arimoclomol in NPC, just as we are reassured about our confidence in arimoclomol as a potential efficacious therapy in this underserved indication. We reiterate our probability rate of high 95% in NPC. Our Base Case at DKK 170 per share stands.

          Regarding the US listing process, we hope to let it have its go and come back with a research note when we know the outcome. So far, the process seems to have put even further pressure on the stock, currently trading well below our Bear Case of DKK 95 per share. In the light of this, it is important for investors to adopt the broader picture; A potential US IPO, together with the current cash position and the potential sale of a Priority Review Voucher, could support the company's operations until cash positive. This is not to mention the equity story that investor buys into the stock; a late-stage orphan pipeline with multiple shots on goal."

          1 Reply Last reply
          2
          • B Offline
            B Offline
            Bador
            wrote on sidst redigeret af
            #5

            Stor forskel på kursen. Den amerikanske kurs svarende til godt 70 kr. lå betragteligt under den danske på godt 74 kr. igår. Siden har den bevæget sig nedad - men det har den amerikanske også!
            Det der undrer mig, er, at den danske stadig ligger væsentligt over den amerikanske? Vil man ind i Orphazymes, er den billigste vej Nasdaq.

            1 Reply Last reply
            0
            • Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktør
              wrote on sidst redigeret af
              #6

              Orphazymes: Den amerikanske notering kan skaffe mere risikovillige investorer:

              https://www.proinvestor.com/investornyt/668028/nasdaq-chef-dobbeltnotering-kan-skaffe-mere-risikovillige-investorer

              1 Reply Last reply
              0
              • D Offline
                D Offline
                deleted-user
                wrote on sidst redigeret af
                #7

                Det kunne sagtens være en bund for nu her i 64,5.
                https://invst.ly/sb072

                1 Reply Last reply
                1
                • B Offline
                  B Offline
                  Bador
                  wrote on sidst redigeret af
                  #8

                  Men det hele skete igår, og der er stadig ikke fodslag mellem kurserne. Jeg kan ikke gennemskue hvorfor.

                  1 Reply Last reply
                  1
                  • D Offline
                    D Offline
                    deleted-user
                    wrote on sidst redigeret af
                    #9

                    Bador - Jeg kan huske da Zealand blev noteret på det amerikanske marked, var der også en del forskel på kursen, ofte blev der ikke handlet så mange aktier, tror ikke det er noget man skal tillægge så stor betydning pt.

                    1 Reply Last reply
                    0
                    • D Offline
                      D Offline
                      deleted-user
                      wrote on sidst redigeret af
                      #10

                      Kunne Orphazyme mon lave en Zealand?

                      Goldmann Sachs, gør det vi andre ikke må,
                      køber 3 stk. hver 10 sek. 😉

                      1 Reply Last reply
                      1

                      Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                      Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                      With your input, this post could be even better 💗

                      Tilmeld Log ind

                      • Log ind

                      • Har du ikke en konto? Tilmeld

                      • Login or register to search.
                      • First post
                        Last post
                      0
                      • Debatforum
                      • Seneste
                      • Populære
                      • Bruger